GPP
JBIO

Great Point Partners’s Jade Biosciences JBIO Stock Holding History

Great Point Partners’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-964,462
Closed -$13.6M – 45
2026
Q1 		$13.6M Buy
964,462
+158,189
+20% +$2.29M 3.11% 13
2025
Q4 		$12.4M Buy
806,273
+173,674
+27% +$2.04M 4.03% 10
2025
Q3 		$5.46M Buy
632,599
+134,545
+27% +$1.1M 2.25% 16
2025
Q2 		$4.98M Buy
+498,054
New +$17M 3.24% 12
2024
Q2 		– Sell
-25,363
Closed -$26.2M – 36
2024
Q1 		$26.2M Sell
25,363
-4,285
-14% -$3.27M 4.09% 8
2023
Q4 		$23.5M Sell
29,648
-1,530
-5% -$780K 4% 9
2023
Q3 		$14.8M Buy
31,178
+4,545
+17% +$2.46M 2.7% 16
2023
Q2 		$16M Buy
26,633
+5,044
+23% +$3.23M 3.13% 15
2023
Q1 		$15.2M Buy
21,589
+10,774
+100% +$8.94M 2.99% 16
2022
Q4 		$11.1M Buy
+10,815
New +$7.85M 2.17% 20

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Great Point Partners's JBIO Position: Q2 2026 in Review

Great Point Partners sold out of Jade Biosciences (JBIO) in Q2 2026, closing a stake of 964,462 shares — an estimated $13.6M sold.

Great Point Partners first reported a position in JBIO in Q4 2022 and held it in 10 quarters. The position peaked at $26.2M in Q1 2024. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Great Point Partners reported no remaining Jade Biosciences position as of Q2 2026 after selling out during the quarter.
  • Great Point Partners sold 964,462 Jade Biosciences shares in Q2 2026, an estimated $13.6M.
  • Great Point Partners first reported a position in Jade Biosciences in Q4 2022 and held it in 10 quarters.
  • Great Point Partners's Jade Biosciences position peaked at $26.2M in Q1 2024.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.